Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 2001 Dec;47:2512–2518.

Identifying and slowing progressive chronic renal failure.

B Curtis 1, B J Barrett 1, A Levin 1
PMCID: PMC2018474  PMID: 11785282

Abstract

OBJECTIVE: To help inform primary care physicians about how to identify and slow progressive chronic renal failure. QUALITY OF EVIDENCE: The National Library of Medicine (1996 to 2000) was searched using PubMed with search terms pertinent to studies on identification, course, and management of chronic renal failure. References in retrieved papers and older literature known to the authors supplemented the searches. In general, sufficient high-quality studies, systematic reviews, or guidelines based on such evidence were available to support our main points. MAIN MESSAGE: End-stage renal disease (ESRD) poses a large and growing morbidity, mortality, and financial burden. Almost all patients reach ESRD as a result of chronic progressive conditions, particularly diabetic nephropathy, hypertensive-vascular renal disease, and glomerular disorders. Patients at risk merit regular renal assessment with serum creatinine tests and urinalysis. Persistent high blood pressure and heavy proteinuria are the strongest predictors of progression of chronic renal failure. Patients with renal disease should be examined and treated for vascular disease and vice versa. Blood pressure lowering, ACE inhibition, and avoidance of further renal insults (such as use of nephrotoxins) can slow the decline of renal function. Restricting dietary protein has a weak effect on slowing renal failure and is not easy to apply in primary care. Timely involvement of specialized nephrology teams is important. CONCLUSION: Family physicians play an important role in recognizing patients with potential for renal failure, in demonstrating progressive chronic renal failure, and in initiating therapy early to improve outcomes.

Full Text

The Full Text of this article is available as a PDF (204.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bargman J. M. Management of minimal lesion glomerulonephritis: evidence-based recommendations. Kidney Int Suppl. 1999 Jun;70:S3–16. doi: 10.1046/j.1523-1755.1999.07002.x. [DOI] [PubMed] [Google Scholar]
  2. Bennett P. H., Haffner S., Kasiske B. L., Keane W. F., Mogensen C. E., Parving H. H., Steffes M. W., Striker G. E. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis. 1995 Jan;25(1):107–112. doi: 10.1016/0272-6386(95)90636-3. [DOI] [PubMed] [Google Scholar]
  3. Biesenbach G., Janko O., Zazgornik J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplant. 1994;9(8):1097–1102. doi: 10.1093/ndt/9.8.1097. [DOI] [PubMed] [Google Scholar]
  4. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  5. Culleton B. F., Larson M. G., Evans J. C., Wilson P. W., Barrett B. J., Parfrey P. S., Levy D. Prevalence and correlates of elevated serum creatinine levels: the Framingham Heart Study. Arch Intern Med. 1999 Aug 9;159(15):1785–1790. doi: 10.1001/archinte.159.15.1785. [DOI] [PubMed] [Google Scholar]
  6. Duncan L., Heathcote J., Djurdjev O., Levin A. Screening for renal disease using serum creatinine: who are we missing? Nephrol Dial Transplant. 2001 May;16(5):1042–1046. doi: 10.1093/ndt/16.5.1042. [DOI] [PubMed] [Google Scholar]
  7. Estacio R. O., Jeffers B. W., Gifford N., Schrier R. W. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000 Apr;23 (Suppl 2):B54–B64. [PubMed] [Google Scholar]
  8. Estacio R. O., Jeffers B. W., Hiatt W. R., Biggerstaff S. L., Gifford N., Schrier R. W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998 Mar 5;338(10):645–652. doi: 10.1056/NEJM199803053381003. [DOI] [PubMed] [Google Scholar]
  9. Fine L. G., Bandyopadhay D., Norman J. T. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int Suppl. 2000 Apr;75:S22–S26. [PubMed] [Google Scholar]
  10. Fouque D., Wang P., Laville M., Boissel J. P. Low protein diets delay end-stage renal disease in non diabetic adults with chronic renal failure. Cochrane Database Syst Rev. 2000;(2):CD001892–CD001892. doi: 10.1002/14651858.CD001892. [DOI] [PubMed] [Google Scholar]
  11. Giatras I., Lau J., Levey A. S. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med. 1997 Sep 1;127(5):337–345. doi: 10.7326/0003-4819-127-5-199709010-00001. [DOI] [PubMed] [Google Scholar]
  12. Goeree R., Manalich J., Grootendorst P., Beecroft M. L., Churchill D. N. Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin Invest Med. 1995 Dec;18(6):455–464. [PubMed] [Google Scholar]
  13. Hansson L., Zanchetti A., Carruthers S. G., Dahlöf B., Elmfeldt D., Julius S., Ménard J., Rahn K. H., Wedel H., Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998 Jun 13;351(9118):1755–1762. doi: 10.1016/s0140-6736(98)04311-6. [DOI] [PubMed] [Google Scholar]
  14. He J., Whelton P. K. Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease. J Hypertens Suppl. 1999 Jun;17(2):S7–13. [PubMed] [Google Scholar]
  15. Hunsicker L. G., Adler S., Caggiula A., England B. K., Greene T., Kusek J. W., Rogers N. L., Teschan P. E. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997 Jun;51(6):1908–1919. doi: 10.1038/ki.1997.260. [DOI] [PubMed] [Google Scholar]
  16. Jindal K. K. Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: evidence-based recommendations. Kidney Int Suppl. 1999 Jun;70:S33–S40. doi: 10.1046/j.1523-1755.1999.07005.x. [DOI] [PubMed] [Google Scholar]
  17. Joffres M. R., Ghadirian P., Fodor J. G., Petrasovits A., Chockalingam A., Hamet P. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens. 1997 Oct;10(10 Pt 1):1097–1102. doi: 10.1016/s0895-7061(97)00224-0. [DOI] [PubMed] [Google Scholar]
  18. Kannel W. B., Stampfer M. J., Castelli W. P., Verter J. The prognostic significance of proteinuria: the Framingham study. Am Heart J. 1984 Nov;108(5):1347–1352. doi: 10.1016/0002-8703(84)90763-4. [DOI] [PubMed] [Google Scholar]
  19. Kasiske B. L., Lakatua J. D., Ma J. Z., Louis T. A. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998 Jun;31(6):954–961. doi: 10.1053/ajkd.1998.v31.pm9631839. [DOI] [PubMed] [Google Scholar]
  20. Keane W. F. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis. 2000 Apr;35(4 Suppl 1):S97–105. doi: 10.1016/s0272-6386(00)70237-x. [DOI] [PubMed] [Google Scholar]
  21. Klahr S., Levey A. S., Beck G. J., Caggiula A. W., Hunsicker L., Kusek J. W., Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994 Mar 31;330(13):877–884. doi: 10.1056/NEJM199403313301301. [DOI] [PubMed] [Google Scholar]
  22. Klahr S., Schreiner G., Ichikawa I. The progression of renal disease. N Engl J Med. 1988 Jun 23;318(25):1657–1666. doi: 10.1056/NEJM198806233182505. [DOI] [PubMed] [Google Scholar]
  23. Laupacis A., Keown P., Pus N., Krueger H., Ferguson B., Wong C., Muirhead N. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 1996 Jul;50(1):235–242. doi: 10.1038/ki.1996.307. [DOI] [PubMed] [Google Scholar]
  24. Lazarus J. M., Bourgoignie J. J., Buckalew V. M., Greene T., Levey A. S., Milas N. C., Paranandi L., Peterson J. C., Porush J. G., Rauch S. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension. 1997 Feb;29(2):641–650. doi: 10.1161/01.hyp.29.2.641. [DOI] [PubMed] [Google Scholar]
  25. Levey A. S., Bosch J. P., Lewis J. B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999 Mar 16;130(6):461–470. doi: 10.7326/0003-4819-130-6-199903160-00002. [DOI] [PubMed] [Google Scholar]
  26. Levey A. S., Perrone R. D., Madias N. E. Serum creatinine and renal function. Annu Rev Med. 1988;39:465–490. doi: 10.1146/annurev.me.39.020188.002341. [DOI] [PubMed] [Google Scholar]
  27. Levin A. Management of membranoproliferative glomerulonephritis: evidence-based recommendations. Kidney Int Suppl. 1999 Jun;70:S41–S46. doi: 10.1046/j.1523-1755.1999.07006.x. [DOI] [PubMed] [Google Scholar]
  28. Lewis E. J., Hunsicker L. G., Bain R. P., Rohde R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11;329(20):1456–1462. doi: 10.1056/NEJM199311113292004. [DOI] [PubMed] [Google Scholar]
  29. Lindeman R. D., Tobin J., Shock N. W. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985 Apr;33(4):278–285. doi: 10.1111/j.1532-5415.1985.tb07117.x. [DOI] [PubMed] [Google Scholar]
  30. Locatelli F., Del Vecchio L., Andrulli S., Marai P., Tentori F. The role of underlying nephropathy in the progression of renal disease. Kidney Int Suppl. 2000 Apr;75:S49–S55. [PubMed] [Google Scholar]
  31. Locatelli F., Marcelli D., Comelli M., Alberti D., Graziani G., Buccianti G., Redaelli B., Giangrande A. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group. Nephrol Dial Transplant. 1996 Mar;11(3):461–467. doi: 10.1093/ndt/11.3.461. [DOI] [PubMed] [Google Scholar]
  32. Marcantoni C., Jafar T. H., Oldrizzi L., Levey A. S., Maschio G. The role of systemic hypertension in the progression of nondiabetic renal disease. Kidney Int Suppl. 2000 Apr;75:S44–S48. [PubMed] [Google Scholar]
  33. Meltzer S., Leiter L., Daneman D., Gerstein H. C., Lau D., Ludwig S., Yale J. F., Zinman B., Lillie D. 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. CMAJ. 1998;159 (Suppl 8):S1–29. [PMC free article] [PubMed] [Google Scholar]
  34. Mendelssohn D. C., Barrett B. J., Brownscombe L. M., Ethier J., Greenberg D. E., Kanani S. D., Levin A., Toffelmire E. B. Elevated levels of serum creatinine: recommendations for management and referral. CMAJ. 1999 Aug 24;161(4):413–417. [PMC free article] [PubMed] [Google Scholar]
  35. Muirhead N. Management of idiopathic membranous nephropathy: evidence-based recommendations. Kidney Int Suppl. 1999 Jun;70:S47–S55. doi: 10.1046/j.1523-1755.1999.07007.x. [DOI] [PubMed] [Google Scholar]
  36. Muntner P., Coresh J., Smith J. C., Eckfeldt J., Klag M. J. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000 Jul;58(1):293–301. doi: 10.1046/j.1523-1755.2000.00165.x. [DOI] [PubMed] [Google Scholar]
  37. Nolin L., Courteau M. Management of IgA nephropathy: evidence-based recommendations. Kidney Int Suppl. 1999 Jun;70:S56–S62. doi: 10.1046/j.1523-1755.1999.07008.x. [DOI] [PubMed] [Google Scholar]
  38. Oldrizzi L., Rugiu C., De Biase V., Maschio G. The place of hypertension among the risk factors for renal function in chronic renal failure. Am J Kidney Dis. 1993 May;21(5 Suppl 2):119–123. doi: 10.1016/s0272-6386(12)70115-4. [DOI] [PubMed] [Google Scholar]
  39. Orth S. R., Stöckmann A., Conradt C., Ritz E., Ferro M., Kreusser W., Piccoli G., Rambausek M., Roccatello D., Schäfer K. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int. 1998 Sep;54(3):926–931. doi: 10.1046/j.1523-1755.1998.00067.x. [DOI] [PubMed] [Google Scholar]
  40. Parving H. H. The impact of hypertension and antihypertensive treatment on the course and prognosis of diabetic nephropathy. J Hypertens Suppl. 1990 Dec;8(7):S187–S191. [PubMed] [Google Scholar]
  41. Perneger T. V., Brancati F. L., Whelton P. K., Klag M. J. End-stage renal disease attributable to diabetes mellitus. Ann Intern Med. 1994 Dec 15;121(12):912–918. doi: 10.7326/0003-4819-121-12-199412150-00002. [DOI] [PubMed] [Google Scholar]
  42. Perneger T. V., Klag M. J., Feldman H. I., Whelton P. K. Projections of hypertension-related renal disease in middle-aged residents of the United States. JAMA. 1993 Mar 10;269(10):1272–1277. [PubMed] [Google Scholar]
  43. Perry H. M., Jr, Miller J. P., Fornoff J. R., Baty J. D., Sambhi M. P., Rutan G., Moskowitz D. W., Carmody S. E. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension. 1995 Apr;25(4 Pt 1):587–594. doi: 10.1161/01.hyp.25.4.587. [DOI] [PubMed] [Google Scholar]
  44. Ravid M., Brosh D., Levi Z., Bar-Dayan Y., Ravid D., Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998 Jun 15;128(12 Pt 1):982–988. doi: 10.7326/0003-4819-128-12_part_1-199806150-00004. [DOI] [PubMed] [Google Scholar]
  45. Ravid M., Lang R., Rachmani R., Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med. 1996 Feb 12;156(3):286–289. [PubMed] [Google Scholar]
  46. Regalado M., Yang S., Wesson D. E. Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. Am J Kidney Dis. 2000 Apr;35(4):687–694. doi: 10.1016/s0272-6386(00)70017-5. [DOI] [PubMed] [Google Scholar]
  47. Remuzzi G., Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998 Nov 12;339(20):1448–1456. doi: 10.1056/NEJM199811123392007. [DOI] [PubMed] [Google Scholar]
  48. Ruggenenti P., Gambara V., Perna A., Bertani T., Remuzzi G. The nephropathy of non-insulin-dependent diabetes: predictors of outcome relative to diverse patterns of renal injury. J Am Soc Nephrol. 1998 Dec;9(12):2336–2343. doi: 10.1681/ASN.V9122336. [DOI] [PubMed] [Google Scholar]
  49. Ruggenenti P., Gaspari F., Perna A., Remuzzi G. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ. 1998 Feb 14;316(7130):504–509. doi: 10.1136/bmj.316.7130.504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Ruggenenti P., Perna A., Gherardi G., Gaspari F., Benini R., Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet. 1998 Oct 17;352(9136):1252–1256. doi: 10.1016/s0140-6736(98)04433-x. [DOI] [PubMed] [Google Scholar]
  51. Ruilope L. M., Rodicio J. L. Clinical relevance of proteinuria and microalbuminuria. Curr Opin Nephrol Hypertens. 1993 Nov;2(6):962–967. doi: 10.1097/00041552-199311000-00017. [DOI] [PubMed] [Google Scholar]
  52. Samuelsson O., Mulec H., Knight-Gibson C., Attman P. O., Kron B., Larsson R., Weiss L., Wedel H., Alaupovic P. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant. 1997 Sep;12(9):1908–1915. doi: 10.1093/ndt/12.9.1908. [DOI] [PubMed] [Google Scholar]
  53. Sarnak M. J., Levey A. S. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000 Apr;35(4 Suppl 1):S117–S131. doi: 10.1016/s0272-6386(00)70239-3. [DOI] [PubMed] [Google Scholar]
  54. Schmitz A., Vaeth M. Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. Diabet Med. 1988 Mar;5(2):126–134. doi: 10.1111/j.1464-5491.1988.tb00958.x. [DOI] [PubMed] [Google Scholar]
  55. Tatti P., Pahor M., Byington R. P., Di Mauro P., Guarisco R., Strollo G., Strollo F. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998 Apr;21(4):597–603. doi: 10.2337/diacare.21.4.597. [DOI] [PubMed] [Google Scholar]
  56. Walker W. G., Neaton J. D., Cutler J. A., Neuwirth R., Cohen J. D. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA. 1992 Dec 2;268(21):3085–3091. [PubMed] [Google Scholar]
  57. Walser M. Progression of chronic renal failure in man. Kidney Int. 1990 May;37(5):1195–1210. doi: 10.1038/ki.1990.103. [DOI] [PubMed] [Google Scholar]
  58. Waugh N. R., Robertson A. M. Protein restriction for diabetic renal disease. Cochrane Database Syst Rev. 2000;(2):CD002181–CD002181. doi: 10.1002/14651858.CD002181. [DOI] [PubMed] [Google Scholar]
  59. Yudkin J. S., Forrest R. D., Jackson C. A. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet. 1988 Sep 3;2(8610):530–533. doi: 10.1016/s0140-6736(88)92657-8. [DOI] [PubMed] [Google Scholar]
  60. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 Jan 20;342(3):145–153. doi: 10.1056/NEJM200001203420301. [DOI] [PubMed] [Google Scholar]
  61. Zucchelli P., Zuccalà A., Borghi M., Fusaroli M., Sasdelli M., Stallone C., Sanna G., Gaggi R. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int. 1992 Aug;42(2):452–458. doi: 10.1038/ki.1992.309. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES